Atul Varadhachary Email and Phone Number
Atul Varadhachary work email
- Valid
- Valid
- Valid
- Valid
- Valid
Atul Varadhachary personal email
Atul Varadhachary phone numbers
CEO | Life Sciences Entrepreneur | Non-Profit Advocate | TeacherI am a physician scientist with over three decades in product development. I am also passionate about mentorship/talent development, and supporting community and philanthropic organizations. My medical training was at the University of Mumbai and my PhD from the Johns Hopkins School of Medicine.As CEO of Radiomer Therapeutics, Inc., I lead development of targeted radiopharmaceuticals/radioligand therapies using our novel Raptamer platform. Radiomer, a spin-out from Fannin, will enter clinic in 1H2025.As Managing Partner at Fannin, I help lead the most active early-stage life sciences development group in Texas. I have previously served as President & COO at Agennix, advancing our lead drug into Phase 3 clinical trials and a successful sale, as Senior Engagement Manager at McKinsey & Co., and President of U.S. Operations for Reliance Life Sciences.Fannin's part-time and full-time talent development programs nurture product developers. Our 350 alumni are active in major pharma/biotech/device companies, biomedical startups, investors, and academic institutions. I have served as Adjunct Professor at Rice, BCM, and UTH for over 30 years and participate in local initiatives to mentor and educate young professionals in Houston.I have supported community and philanthropic organizations throughout my career. While on leave from McKinsey, I co-founded and ran Pratham Health (now the Niramaya Health Foundation), a preventive health program reaching 65,000 underprivileged preschool children in India. I remain engaged with Pratham, the world’s largest educational non-profit, having served as founding director and President of Pratham USA and on the Pratham global board. Pratham’s programs have garnered international recognition, including the Asia Game Changer Award, Kravis Prize for Leadership, Lui Che Woo Prize, Skoll Award for Social Entrepreneurship, and Wise Prize for Education.I have served on multiple boards in Texas, including the Harris Health System, Every Texan, and BioHouston, and held leadership roles as President of TiE Houston and the Indo-American Chamber of Commerce of Greater Houston (IACCGH). I have also served on multiple advisory boards, including at the American Cancer Society (ACS), BIO, Cancer Prevention and Research Institute of Texas (CPRIT), Greater Houston Partnership (GHP), Houston Community College, Houston Technology Center, MD Anderson Cancer Center, Rice University, Texas Children’s Hospital, University of Houston, University of Texas, and UTMB.
-
Executive ChairAllterum TherapeuticsBellaire, Tx, Us
-
Chief Executive OfficerRadiomer Therapeutics Jan 2024 - PresentHouston, Texas, UsRadiomer Therapeutics, Inc. is developing targeted radiopharmaceuticals (radioligand therapeutics) for therapeutic and diagnostic applications using its novel, Raptamer (peptide-oligonucleotide hybrid) platform. Radiomer Therapeutics has been spun out of Fannin and expects to enter clinic in 1H 2025. -
Managing PartnerFannin Jun 2013 - PresentHouston, Texas, UsFannin is the most active early-stage life sciences development group in Texas. Fannin has over a dozen active biotech and medtech programs including two in the clinic and one in commercialization. These include assets and technologies that are in-licensed from academic institutions and those that we develop internally. Total investment across our programs exceeds $275 million. Fannin's approach to early-stage commercialization of academic research complements the more traditional academic paths of either out-licensing the technology to industry or spinning it out as a standalone VC-funded startup. In our hybrid approach, Fannin serves as both the management team and the early investor, collaborating with the academic inventors to advance the technology, leveraging grant funding when appropriate. When appropriately de-risked, we spin the programs out with dedicated management teams and outside funding. We evolved this approach to help address the biotech development gap in places, like Houston, that have a powerful research engine, but lack the critical mass of product development and commercialization seen in the major biotech hubs.An additional critical element to our model is helping grow our life sciences entrepreneurs locally through our talent development programs. Our program includes part-time interns and full-time fellows/product development associates, the latter accredited by the Department of Labor. Our talent development program has grown to become one of the largest of its kind, with over 320 interns, fellows, and associates in the last seven years, with our alumni active in institutions and biotech companies across our ecosystem and nationally.Below is a link to a recent podcast discussing our model:http://tinyurl.com/Atul-Podcast-Innov-Map-2024 -
Chief Executive OfficerAllterum Therapeutics Jul 2018 - PresentHouston, Texas, UsAllterum Therapeutics, Inc., is developing 4A10, a first-in- class drug for treating CD127+ (IL-7R) cancers, which will enter clinical testing in 1H 2025. We will enter clinic in patients with Acute Lymphoblastic Leukemia (ALL), with expansion into other CD127+ hematological cancers including lymphomas, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL). Our developmental pipeline includes a CD127-targeting drug conjugate (CD127- DC) for solid tumors as CD127 is expressed by significant subsets of patients with lung, breast, colorectal, esophageal, and head & neck (H&N) cancers.4A10 has robust pre-clinical efficacy data and a strong safety profile including results from non-human primate (NHP) studies. 4A10 was created by Dr. Scott Durum at the National Cancer Institute (NCI) and licensed exclusively to Allterum.
-
Member, Advisory Committee On Childhood CancersCancer Prevention And Research Institute Of Texas Jan 2023 - PresentAustin, Texas, Us -
Ceos Against CancerAmerican Cancer Society Jan 2019 - PresentAtlanta, Ga, Us -
Member Board Of DirectorsBiohouston Jan 2018 - PresentHouston, Tx, Us -
Member, Board Of DirectorsPulmotect, Inc. Sep 2012 - PresentPulmotect, Inc. is a Houston-based biotechnology company, developing products that boost the innate immune system to protect against a wide range of lung infections. Our lead product stimulates the body’s natural defenses to provide rapid, broad-spectrum, anti-infective activity against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague).
-
President (2019-2021), Board Member, Charter MemberTie Jan 2013 - PresentSanta Clara, California, UsTiE, founded in 1992 in Silicon Valley, is one of the largest entrepreneurship organizations in the world. TiE has over 11,000 members including over 2,500 charter members in 60 chapters across 17 countries. TiE’s mission is to foster entrepreneurship globally through mentoring, networking, and education. -
Adjunct Professor Of ManagementRice University Jan 2003 - PresentHouston, Tx, UsAtul has taught Entrepreneurship in Biotechnology at the Jones Graduate School of Business since 2003. -
Multiple Roles: Founding Director & President, Pratham Usa; Director, Pratham Education FoundationPratham Usa Nov 1998 - PresentInAbout Pratham Pratham (www.pratham.org), which means "first" in Sanskrit, was founded with UNICEF support in underserved communities of Mumbai in 1994. Today, Pratham is one of the largest non-profit organizations in the field of education, working in sixteen Indian states, in over 150 rural districts and 30 cities. In 2005, Pratham pioneered a nation-wide assessment of learning (Annual Status of Education Report) that has influenced national educational policies and budget allocations. Pratham’s flagship Read India program aims to correct the problem of learning outcomes, annually reaching over two million children in over 20,000 villages across India. Over the years Pratham has expanded beyond an initial focus on preschool and primary school children to include school drop-outs as well as youth who need vocational skills to enter the job market.Pratham has been recognized internationally for its innovation and large-scale impact. Awards include the Kravis Prize for Leadership, the Skoll Award for Social Entrepreneurship, and most recently the WISE Prize for Education that was awarded to Pratham co-founder and CEO, Dr. Madhav Chavan. About Pratham USA: Pratham USA (www.prathamusa.org) is a 501(c)(3) nonprofit organization with has been awarded a four-star rating, the highest possible, from Charity Navigator for the past 6 consecutive years. Pratham USA currently has chapters in fifteen cities throughout the United States. The organization accepts tax deductible contributions from U.S. donors to support the mission of Pratham in India to ensure that “Every child is in school and learning well.”For more information, visit www.pratham.org or www.prathamusa.org -
Member Board Of DirectorsEvery Texan May 2013 - Mar 2023Austin, Tx, UsThe Center for Public Policy Priorities is a nonpartisan, nonprofit policy institute committed to improving public policies to make a better Texas -
Health Care Advisory CommitteeGreater Houston Partnership Jan 2018 - 2023Houston, Tx, Us -
President, U.S. OperationsReliance Life Sciences Jan 2011 - May 2013Navi Mumbai, Maharashtra, InReliance Life Sciences (RLS) is among the more diverse integrated life sciences companies in the world. RLS is part of the Reliance Group of Industries, India's largest private sector enterprise with $30 billion in annual revenues. RLS's range of business units include (i) a full-service CRO (the leading local CRO in India conducting clinical trials from Phase 1 through Phase 4, specialized clinical studies, data management, medical writing, and preclinical safety-tox and pharmacology studies); (ii) diagnostics (molecular diagnostics, flow cytometry, HLA typing, DNA-based infectious disease testing, genetic testing and athology services); (iii) biopharma (marketed products include plasma proteins and recombinant growth factors and a rich pipeline of biogenerics); (iv) pharmaceuticals (drugs marketed in India include capecitabine, pemetrexed, bortezomib, imatinib and erlotinib); and (v) novel therapeutics (including siRNA based molecules entering the clinic). -
Member, Board Of ManagersHarris Health System Jan 2009 - Dec 2012Bellaire, Texas, UsThe Harris Health System (formerly HCHD) primarily serves under-insured patients in Harris County, the third most populous county in the U.S., that includes the city of Houston. The HCHD’s three hospitals, 12 Community Health Centers, a dental center, 13 homeless shelter clinics and four mobile health clinics provides a broad range of health, nutrition, health education and social services to approximately a million under-insured and uninsured people living in Harris County. -
Adjunct ProfessorBaylor College Of Medicine 2003 - 2012
-
President And DirectorIndo-American Chamber Of Commerce Of Greater Houston Jan 2004 - Jan 2010Served as a Director of the IACCGH from 2004 - 2011. Served as Chamber President (2008-09).
-
President & CooAgennix, Inc. May 2001 - Jan 2010Agennix is a publicly traded biotechnology company based in Houston, Princeton and Munich. Agennix’s lead molecule, talactoferrin alfa, is a novel anti-cancer agent in Phase III development for the treatment of patients with lung cancer. Agennix is also in Phase II development with talactoferrin for other cancer indications including Renal (Kidney) cancer, for patients with severe sepsis, and in wound healing.
-
Senior Engagement ManagerMckinsey & Co. Sep 1994 - May 2001Us -
Postdoctoral Fellow In Biological ChemistryJohns Hopkins School Of Medicine 1992 - 1994Baltimore, Md, UsFounding President of the Johns Hopkins Postdoctoral Association, the first postdoctoral association in the U.S.
Atul Varadhachary Skills
Atul Varadhachary Education Details
-
The Johns Hopkins University School Of MedicinePhysiology -
University Of MumbaiMedicine
Frequently Asked Questions about Atul Varadhachary
What company does Atul Varadhachary work for?
Atul Varadhachary works for Allterum Therapeutics
What is Atul Varadhachary's role at the current company?
Atul Varadhachary's current role is Executive Chair.
What is Atul Varadhachary's email address?
Atul Varadhachary's email address is av****@****ion.com
What is Atul Varadhachary's direct phone number?
Atul Varadhachary's direct phone number is +171396*****
What schools did Atul Varadhachary attend?
Atul Varadhachary attended The Johns Hopkins University School Of Medicine, University Of Mumbai.
What skills is Atul Varadhachary known for?
Atul Varadhachary has skills like Biotechnology, Lifesciences, Drug Development, Clinical Development, Clinical Trials, Pharmaceutical Industry, Cancer, Start Ups, Life Sciences, Biopharmaceuticals, Strategy, Clinical Research.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial